List view / Grid view
5 October 2015 | By Victoria White
The Nobel Prize for Physiology or Medicine has been split this year to recognise work that has revolutionised the treatment of some parasitic diseases...
1 October 2015 | By Victoria White
The TaNeDS programme provides close partnership between successful applicants and scientists in Daiichi Sankyo to tackle unmet medical needs...
29 September 2015 | By Victoria White
LDC and Infinity will work together to select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network...
28 September 2015 | By Charles River
This webinar describes an approach to phenotypic discovery through bioprofiling in human primary cell-based assays across several disease areas (case study)...
25 September 2015 | By Victoria White
The team of researchers will comprehensively study human proteomes with the aim of turning the vast amount of molecular information into designs for new reagents, equipment, workflows, assays and software...
24 September 2015 | By Victoria White
Regeneron will provide the ETI with access to VelocImmune technology to generate antibodies against targets of interest and explore potential therapeutic applications for human disease...
24 September 2015 | By Victoria White
Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
24 September 2015 | By Victoria White
Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
22 September 2015 | By Victoria White
The companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets...
21 September 2015 | By Drug Target Review
Included in this issue: Drug Development, Microfluidics, Proteomics, Ion Channels, GPCR, Imaging, Flow Cytometry, Enzymes
21 September 2015 | By Victoria White
Dr Wood's expertise and experience to support Nuevolution in developing its pipeline in oncology, inflammation and immuno-oncology...
In this Proteomics In-Depth Focus: David J. Britton & Pedro R. Cutillas from Barts Cancer Institute ask should LC-MS/MS proteomics guide targeted drug selection for cancer patients? And Manfred Raida from the National University of Singapore explains how mass spectrometry and drug development come together...
21 September 2015 | By Victoria White
Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc...
All biopharmaceutical products are associated with an intrinsic potential to induce immune responses in treated subjects. Regulatory agencies expect sponsors to evaluate and mitigate these risks during product development, applying a strategy that addresses product- and patient-related factors. Overall, understanding and controlling immunogenicity-related risks are attainable objectives, and approvability should…
Microfluidic miniaturisation, or the so-called ‘lab-on-a-chip’ concept, now encroaches on the fields of biology, medicine and pharmacology, and the nature of microfluidic technology (small volumes and high-throughput integration of fluid connections) means that it is outperforming conventional bench work. There has been an incredible need for microfluidic technology in the…
